These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19004143)

  • 1. Management of chronic hepatitis B virus infection: a promising approach using small interfering RNA (siRNA).
    Dwivedi M; Misra SP; Misra V; Waikhom RK; Bhatnagar M
    Natl Med J India; 2008; 21(3):123-7. PubMed ID: 19004143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y; Li Z; Li L; Li J; Liu X; Li W
    Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
    Ren GL; Fang Y; Ma HH; Lei YF; Wang D; Xu MC; Wang PZ; Huang CX; Nie OH; Sun YT; Bai XF
    Antivir Ther; 2007; 12(6):865-76. PubMed ID: 17926641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA.
    Chen CC; Ko TM; Ma HI; Wu HL; Xiao X; Li J; Chang CM; Wu PY; Chen CH; Han JM; Yu CP; Jeng KS; Hu CP; Tao MH
    Gene Ther; 2007 Jan; 14(1):11-9. PubMed ID: 16929350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term RNA interference and its application to hepatitis B virus.
    Pan JS; Wang XZ; Ren JL
    J Dig Dis; 2009 Aug; 10(3):165-71. PubMed ID: 19659783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting the RNA interference pathway to counter hepatitis B virus replication.
    Arbuthnot P; Carmona S; Ely A
    Liver Int; 2005 Feb; 25(1):9-15. PubMed ID: 15698393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus.
    Zhang J; Yamada O; Sakamoto T; Yoshida H; Iwai T; Matsushita Y; Shimamura H; Araki H; Shimotohno K
    Virology; 2004 Mar; 320(1):135-43. PubMed ID: 15003869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice.
    Rauschhuber C; Xu H; Salazar FH; Marion PL; Ehrhardt A
    J Gene Med; 2008 Aug; 10(8):878-89. PubMed ID: 18470951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of bovine viral diarrhea virus replication by small interfering RNA and short hairpin RNA-mediated RNA interference.
    Lambeth LS; Moore RJ; Muralitharan MS; Doran TJ
    Vet Microbiol; 2007 Jan; 119(2-4):132-43. PubMed ID: 17052865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does RNA interference provide new hope for control of chronic hepatitis B infection?
    Wilson R; Purcell D; Netter HJ; Revill PA
    Antivir Ther; 2009; 14(7):879-89. PubMed ID: 19918092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of hepatitis B virus expression and replication by RNA interference.
    Shlomai A; Shaul Y
    Hepatology; 2003 Apr; 37(4):764-70. PubMed ID: 12668968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA therapeutics: big potential from small RNAs.
    Ryther RC; Flynt AS; Phillips JA; Patton JG
    Gene Ther; 2005 Jan; 12(1):5-11. PubMed ID: 15496962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference as a new strategy against viral hepatitis.
    Radhakrishnan SK; Layden TJ; Gartel AL
    Virology; 2004 Jun; 323(2):173-81. PubMed ID: 15193913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery.
    Gary DJ; Puri N; Won YY
    J Control Release; 2007 Aug; 121(1-2):64-73. PubMed ID: 17588702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of adeno-associated viral vector for delivery of small interfering RNA.
    Tomar RS; Matta H; Chaudhary PM
    Oncogene; 2003 Aug; 22(36):5712-5. PubMed ID: 12944921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small interfering RNA for experimental cancer therapy.
    Tong AW; Zhang YA; Nemunaitis J
    Curr Opin Mol Ther; 2005 Apr; 7(2):114-24. PubMed ID: 15844618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference--small RNAs effectively fight viral hepatitis.
    Shlomai A; Shaul Y
    Liver Int; 2004 Dec; 24(6):526-31. PubMed ID: 15566500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference and potential therapeutic applications of short interfering RNAs.
    Karagiannis TC; El-Osta A
    Cancer Gene Ther; 2005 Oct; 12(10):787-95. PubMed ID: 15891770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.